This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Receives $1 Billion From Starboard Value, Stock Rises
by Zacks Equity Research
PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.
Company News for Oct 8, 2024
by Zacks Equity Research
Companies in The News Are: PFE,WYNN,GOOGl,APD
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
by Zacks Equity Research
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
5 Large Drug Stocks to Watch From a Thriving Industry
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $28.61, denoting a -0.21% change from the preceding trading day.
Zacks Investment Ideas feature highlights: Coca-Cola, Pfizer and Altria
by Zacks Equity Research
Coca-Cola, Pfizer and Altria have been highlighted in this Investment Ideas article.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
3 Consistent Dividend Stocks for Passive Income: KO, PFE, MO
by Derek Lewis
Everybody loves dividends, essentially investors' form of payday. And these companies have been paying shareholders consistently for years.
Zacks.com featured highlights include GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer
by Zacks Equity Research
GIII Apparel Group, Sonoco Products, Hamilton Insurance Group, Pampa Energia S.A. and Pfizer are part of the Zacks Screen of the Week article.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
by Zacks Equity Research
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
by Zacks Equity Research
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
Buy These Top 5 Price-to-Sales Stocks for Better Investment Returns
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, SON, HG, PAM and PFE hold promise.
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
by Zacks Equity Research
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
4 High Earnings Yield Stocks That Value Investors Should Buy Now
by Rimmi Singhi
Unlock your portfolio value by investing in these high-earnings stocks like PPC, PFE, IAG and ASIX.
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
by Nalak Das
Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.
Pfizer (PFE) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
by Zacks Equity Research
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
by Zacks Equity Research
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Top Stock Reports for Coca-Cola, Chevron & ServiceNow
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Chevron Corporation (CVX) and ServiceNow, Inc. (NOW), as well as two micro-cap stocks Sypris Solutions, Inc. (SYPR) and Mobile Infrastructure Corporation (BEEP).